Delegate of the Board and Chief Executive Officer of SynDermix AG, Mr. Dieter Hemmer, on medical leave of absence; Dr. Konstantinos Efthymiopoulos appointed Designated Managing Director until the AGM 2020
(more…)

SynDermix AG announced temporary postponement of initiation of the SDX-3101 clinical trial on chronic rhinosinusitis without nasal polyps due to the novel coronavirus pandemic. (more…)

SynDermix AG is pleased to announce the successful completion of the first SIV for the clinical trial of SDX-3101, in preparation for the recruitment of the first patient to the study. (more…)

SynDermix AG is proud to announce its collaboration with King’s College London for the development of its Nitric Oxide technology. (more…)

Shareholders approve all proposals put forward by the Board of Directors and re-elect the Chairman and Directors to the board of SynDermix.
(more…)

SynDermix announces the sale of a majority stake of SDX Cosmetics – formerly a fully owned subsidiary of SynDermix AG. (more…)

The Board of SynDermix announces changes in the management and executive team. (more…)

The Board of Directors announces a successful increase of share capital: A total of CHF 1 000 000 in loans were converted against 232 222 newly issued shares.

The Board of SynDermix is pleased to announce the closure of a new investment of CHF 10 million in the Company as of December 2018. The Company plans to use the proceeds to fund operations, product development and future potential acquisitions.

SynDermix announces the successful kick-off meeting of the project SDX-3103 (more…)